Citizens reiterates market outperform on Lantheus Holdings
Citizens analyst David Turkaly has reiterated a Market Outperform rating for Lantheus Holdings, maintaining a price target of $115. The rating reflects the firm's positive outlook on the stock.
*this image is generated using AI for illustrative purposes only.
Citizens analyst David Turkaly has reaffirmed a Market Outperform rating for Lantheus Holdings, maintaining a price target of $115. The rating reiteration underscores the firm's continued confidence in the company's market performance.
Analyst Rating and Price Target
The research note from Citizens highlights the following key details regarding Lantheus Holdings:
| Metric | Value |
|---|---|
| Rating | Market Outperform |
| Price Target | $115 |
| Analyst | David Turkaly |
The stock is listed on the NASDAQ under the ticker symbol LNTH.
What specific growth drivers does Citizens expect will push Lantheus Holdings toward the $115 price target?
How might recent or upcoming regulatory approvals impact Lantheus's market performance in the near term?
What competitive challenges could Lantheus face in the radiopharmaceuticals market that might affect its outlook?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
